Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers) - Global Forecasts to 2024
“The lymphedema diagnostics market is projected to grow at a CAGR of 7.4% during the forecast period.”
The global lymphedema diagnostics market is projected to reach USD 35 million by 2024 from USD 24 million in 2019, at a CAGR of 7.4%. The major factors driving the growth of this market include the increasing global prevalence of cancer and lymphedema; technological advancements in diagnostic imaging modalities; and increasing investments, funds, and grants by public-private organizations. However, the high cost of diagnostic imaging systems, the short half-life of radiopharmaceuticals, and the limited supply of helium are expected to hinder the growth of this market.
“The lymphoscintigraphy segment accounted for the largest market share in 2018.”
Based on technology, the lymphedema diagnostics market is segmented into lymphoscintigraphy, magnetic resonance imaging (MRI), ultrasound imaging, computed tomography (CT), X-ray lymphography, bioimpedance analysis, and near-infrared fluorescence imaging. The lymphoscintigraphy segment accounted for the largest share of the lymphedema diagnostics market in 2018. The noninvasive nature and easy reproducibility of this technology, and the fact that lymphoscintigraphy does not adversely affect the lymphatic vascular endothelium are some of the key advantages supporting the adoption of this technology.
“The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018.”
On the basis of disease type, the lymphedema diagnostics market is segmented into cancer, inflammatory diseases, cardiovascular disease, and other diseases (congenital abnormalities, trauma-related conditions, infections, and filariasis). The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018. The large share of this segment can be attributed to the rising prevalence of cancer-associated lymphedema and increasing awareness about early disease diagnosis.
“Europe to account for the second-largest share of the global market in 2019.”
The lymphedema diagnostics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe is expected to account for the second-largest share of the global lymphedema diagnostics market in 2019. The rising incidence of chronic diseases and injuries, growing demand for early diagnosis and treatment, technological advancements, product launches, and increasing government and public-private investments for developing novel diagnostic imaging modalities are the major factors driving market growth in Europe.
Breakdown of supply-side primary interviews:
Research Coverage
This report studies the lymphedema diagnostics market based on technology, disease type, end user, and region. The report also studies factors (such as drivers and restraints) affecting market growth. In addition, it analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions (and the respective countries in these regions).
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The global lymphedema diagnostics market is projected to reach USD 35 million by 2024 from USD 24 million in 2019, at a CAGR of 7.4%. The major factors driving the growth of this market include the increasing global prevalence of cancer and lymphedema; technological advancements in diagnostic imaging modalities; and increasing investments, funds, and grants by public-private organizations. However, the high cost of diagnostic imaging systems, the short half-life of radiopharmaceuticals, and the limited supply of helium are expected to hinder the growth of this market.
“The lymphoscintigraphy segment accounted for the largest market share in 2018.”
Based on technology, the lymphedema diagnostics market is segmented into lymphoscintigraphy, magnetic resonance imaging (MRI), ultrasound imaging, computed tomography (CT), X-ray lymphography, bioimpedance analysis, and near-infrared fluorescence imaging. The lymphoscintigraphy segment accounted for the largest share of the lymphedema diagnostics market in 2018. The noninvasive nature and easy reproducibility of this technology, and the fact that lymphoscintigraphy does not adversely affect the lymphatic vascular endothelium are some of the key advantages supporting the adoption of this technology.
“The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018.”
On the basis of disease type, the lymphedema diagnostics market is segmented into cancer, inflammatory diseases, cardiovascular disease, and other diseases (congenital abnormalities, trauma-related conditions, infections, and filariasis). The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018. The large share of this segment can be attributed to the rising prevalence of cancer-associated lymphedema and increasing awareness about early disease diagnosis.
“Europe to account for the second-largest share of the global market in 2019.”
The lymphedema diagnostics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe is expected to account for the second-largest share of the global lymphedema diagnostics market in 2019. The rising incidence of chronic diseases and injuries, growing demand for early diagnosis and treatment, technological advancements, product launches, and increasing government and public-private investments for developing novel diagnostic imaging modalities are the major factors driving market growth in Europe.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (25%), Tier 2 (30%), and Tier 3 (42%)
- By Designation: C-level (26%), Director-level (30%), and Others (44%)
- By Region: North America (34%), Europe (26%), APAC (23%), and RoW (17%)
Research Coverage
This report studies the lymphedema diagnostics market based on technology, disease type, end user, and region. The report also studies factors (such as drivers and restraints) affecting market growth. In addition, it analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions (and the respective countries in these regions).
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and challenges.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 PRODUCT-BASED MARKET ESTIMATION
2.2.2 PRIMARY RESEARCH VALIDATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH LIMITATIONS AND ASSUMPTIONS
2.4.1 LIMITATIONS
2.4.2 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 LYMPHEDEMA DIAGNOSTICS: MARKET OVERVIEW
4.2 REGIONAL ANALYSIS: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE (2019)
4.3 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
4.4 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
4.5 LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing global prevalence of lymphedema
5.2.1.2 Growing global prevalence of cancer
5.2.1.3 Technological advancements and adoption of newer diagnostic modalities
5.2.1.4 Increasing investments, funds, and grants by public-private organizations
5.2.2 RESTRAINTS
5.2.2.1 High cost of diagnostic imaging systems
5.2.2.2 Short half-life of radiopharmaceuticals
5.2.2.3 Limited supply of helium
5.2.2.4 Increasing adoption of refurbished diagnostic imaging systems
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging countries
5.2.4 CHALLENGES
5.2.4.1 Hospital budget cuts
6 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
6.2 LYMPHOSCINTIGRAPHY
6.2.1 LYMPHOSCINTIGRAPHY IS RAPIDLY DEVELOPING TO BE THE FIRST-LINE IMAGING MODALITY FOR LYMPHEDEMA DIAGNOSTICS
6.3 MAGNETIC RESONANCE IMAGING
6.3.1 MAGNETIC RESONANCE IMAGING FINDS MAJOR APPLICATIONS IN LYMPHEDEMA TREATMENT PLANNING
6.4 ULTRASOUND IMAGING
6.4.1 ULTRASOUND IMAGING HAS THE POTENTIAL TO DETERMINE TISSUE CHANGES CONSISTENT WITH DIFFERENT STAGES OF LYMPHEDEMA
6.5 COMPUTED TOMOGRAPHY
6.5.1 HIGH COST OF COMPUTED TOMOGRAPHY TO LIMIT MARKET GROWTH
6.6 X-RAY LYMPHOGRAPHY
6.6.1 INVASIVE NATURE & RISK OF RADIATION EXPOSURE ARE EXPECTED TO HAMPER MARKET GROWTH
6.7 BIOIMPEDANCE ANALYSIS
6.7.1 LACK OF AWARENESS ABOUT BIOIMPEDANCE ANALYSIS IS LIMITING THE GROWTH OF THIS SEGMENT
6.8 NEAR-INFRARED FLUORESCENCE IMAGING
6.8.1 ICG LYMPHOGRAPHY
6.8.1.1 ICG lymphography offers a powerful tool for efficiently diagnosing various stages of lymphedema
6.8.2 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY
6.8.2.1 Fluorescein sodium microlymphangiography is limited to visualizing only initial capillaries
7 LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE
7.1 INTRODUCTION
7.2 CANCER
7.2.1 ONE IN THREE CANCER-TREATED PATIENTS DEVELOP LYMPHEDEMA
7.3 INFLAMMATORY DISEASES
7.3.1 GROWING PREVALENCE OF INFLAMMATORY CONDITIONS
TO DRIVE MARKET GROWTH
7.4 CARDIOVASCULAR DISEASE
7.4.1 GROWING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS
TO DRIVE THE ADOPTION OF LYMPHEDEMA DIAGNOSTIC TOOLS
7.5 OTHER DISEASES
8 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 THE LARGE NUMBER OF LYMPHEDEMA DIAGNOSTIC PROCEDURES PERFORMED IN HOSPITALS TO DRIVE MARKET GROWTH
8.3 DIAGNOSTIC CENTERS
8.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
8.4 RESEARCH & ACADEMIC INSTITUTES
8.4.1 BUDGETARY RESTRICTIONS OF RESEARCHERS ARE LIMITING THE ADOPTION OF HIGH-END LYMPHEDEMA DIAGNOSTIC TECHNOLOGIES
8.5 OTHER END USERS
9 LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 The US dominated the North American market in 2018
9.2.2 CANADA
9.2.2.1 Dearth of radiologists is restricting market growth in Canada
9.3 EUROPE
9.3.1 GERMANY
9.3.1.1 Germany accounts for the largest share of the European market
9.3.2 FRANCE
9.3.2.1 Uncertainties with regard to the pricing strategy of diagnostic companies to limit market growth in France to a certain extent
9.3.3 UK
9.3.3.1 Rising diagnostic imaging procedural volumes indicate strong growth in the UK market
9.3.4 ROE
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.1.1 Rising disease incidence, increasing procedural volumes, and growth in the geriatric population have contributed to market growth in China
9.4.2 JAPAN
9.4.2.1 Japan’s well-established and well-equipped healthcare system ensures demand for and easy access to diagnostic imaging
9.4.3 INDIA
9.4.3.1 Growing incidence of lymphatic filariasis is a key contributor to market growth
9.4.4 ROAPAC
9.5 REST OF THE WORLD
9.5.1 LATIN AMERICA
9.5.1.1 Latin America holds the largest share of the RoW market
9.5.2 MIDDLE EAST & AFRICA
9.5.2.1 Growing geriatric population & disease prevalence are driving growth in MEA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 RANKING OF PLAYERS, 2018
10.3 COMPETITIVE SCENARIO
10.4 VENDOR DIVE OVERVIEW
10.5 VENDOR INCLUSION CRITERIA
10.6 VENDOR DIVE
10.6.1 VISIONARY LEADERS
10.6.2 INNOVATORS
10.6.3 DYNAMIC DIFFERENTIATORS
10.6.4 EMERGING COMPANIES
11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 GE HEALTHCARE
11.2 SIEMENS HEALTHINEERS (A SUBSIDIARY OF SIEMENS GROUP)
11.3 PHILIPS
11.4 CANON, INC.
11.5 SHIMADZU CORPORATION
11.6 STRYKER CORPORATION
11.7 FLUOPTICS
11.8 UNITED IMAGING HEALTHCARE CO., LTD.
11.9 HITACHI, LTD.
11.10 ESAOTE SPA
11.11 NEUSOFT CORPORATION
11.12 MINDRAY MEDICAL INTERNATIONAL LIMITED (A SUBSIDIARY OF
EXCELSIOR UNION, LTD.)
11.13 MITAKA USA, INC.
11.14 CURADEL, LLC
11.15 IMPEDIMED LIMITED
11.16 OTHER COMPANIES
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 PRODUCT-BASED MARKET ESTIMATION
2.2.2 PRIMARY RESEARCH VALIDATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH LIMITATIONS AND ASSUMPTIONS
2.4.1 LIMITATIONS
2.4.2 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 LYMPHEDEMA DIAGNOSTICS: MARKET OVERVIEW
4.2 REGIONAL ANALYSIS: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE (2019)
4.3 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
4.4 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
4.5 LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing global prevalence of lymphedema
5.2.1.2 Growing global prevalence of cancer
5.2.1.3 Technological advancements and adoption of newer diagnostic modalities
5.2.1.4 Increasing investments, funds, and grants by public-private organizations
5.2.2 RESTRAINTS
5.2.2.1 High cost of diagnostic imaging systems
5.2.2.2 Short half-life of radiopharmaceuticals
5.2.2.3 Limited supply of helium
5.2.2.4 Increasing adoption of refurbished diagnostic imaging systems
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging countries
5.2.4 CHALLENGES
5.2.4.1 Hospital budget cuts
6 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
6.2 LYMPHOSCINTIGRAPHY
6.2.1 LYMPHOSCINTIGRAPHY IS RAPIDLY DEVELOPING TO BE THE FIRST-LINE IMAGING MODALITY FOR LYMPHEDEMA DIAGNOSTICS
6.3 MAGNETIC RESONANCE IMAGING
6.3.1 MAGNETIC RESONANCE IMAGING FINDS MAJOR APPLICATIONS IN LYMPHEDEMA TREATMENT PLANNING
6.4 ULTRASOUND IMAGING
6.4.1 ULTRASOUND IMAGING HAS THE POTENTIAL TO DETERMINE TISSUE CHANGES CONSISTENT WITH DIFFERENT STAGES OF LYMPHEDEMA
6.5 COMPUTED TOMOGRAPHY
6.5.1 HIGH COST OF COMPUTED TOMOGRAPHY TO LIMIT MARKET GROWTH
6.6 X-RAY LYMPHOGRAPHY
6.6.1 INVASIVE NATURE & RISK OF RADIATION EXPOSURE ARE EXPECTED TO HAMPER MARKET GROWTH
6.7 BIOIMPEDANCE ANALYSIS
6.7.1 LACK OF AWARENESS ABOUT BIOIMPEDANCE ANALYSIS IS LIMITING THE GROWTH OF THIS SEGMENT
6.8 NEAR-INFRARED FLUORESCENCE IMAGING
6.8.1 ICG LYMPHOGRAPHY
6.8.1.1 ICG lymphography offers a powerful tool for efficiently diagnosing various stages of lymphedema
6.8.2 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY
6.8.2.1 Fluorescein sodium microlymphangiography is limited to visualizing only initial capillaries
7 LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE
7.1 INTRODUCTION
7.2 CANCER
7.2.1 ONE IN THREE CANCER-TREATED PATIENTS DEVELOP LYMPHEDEMA
7.3 INFLAMMATORY DISEASES
7.3.1 GROWING PREVALENCE OF INFLAMMATORY CONDITIONS
TO DRIVE MARKET GROWTH
7.4 CARDIOVASCULAR DISEASE
7.4.1 GROWING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS
TO DRIVE THE ADOPTION OF LYMPHEDEMA DIAGNOSTIC TOOLS
7.5 OTHER DISEASES
8 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 THE LARGE NUMBER OF LYMPHEDEMA DIAGNOSTIC PROCEDURES PERFORMED IN HOSPITALS TO DRIVE MARKET GROWTH
8.3 DIAGNOSTIC CENTERS
8.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
8.4 RESEARCH & ACADEMIC INSTITUTES
8.4.1 BUDGETARY RESTRICTIONS OF RESEARCHERS ARE LIMITING THE ADOPTION OF HIGH-END LYMPHEDEMA DIAGNOSTIC TECHNOLOGIES
8.5 OTHER END USERS
9 LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 The US dominated the North American market in 2018
9.2.2 CANADA
9.2.2.1 Dearth of radiologists is restricting market growth in Canada
9.3 EUROPE
9.3.1 GERMANY
9.3.1.1 Germany accounts for the largest share of the European market
9.3.2 FRANCE
9.3.2.1 Uncertainties with regard to the pricing strategy of diagnostic companies to limit market growth in France to a certain extent
9.3.3 UK
9.3.3.1 Rising diagnostic imaging procedural volumes indicate strong growth in the UK market
9.3.4 ROE
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.1.1 Rising disease incidence, increasing procedural volumes, and growth in the geriatric population have contributed to market growth in China
9.4.2 JAPAN
9.4.2.1 Japan’s well-established and well-equipped healthcare system ensures demand for and easy access to diagnostic imaging
9.4.3 INDIA
9.4.3.1 Growing incidence of lymphatic filariasis is a key contributor to market growth
9.4.4 ROAPAC
9.5 REST OF THE WORLD
9.5.1 LATIN AMERICA
9.5.1.1 Latin America holds the largest share of the RoW market
9.5.2 MIDDLE EAST & AFRICA
9.5.2.1 Growing geriatric population & disease prevalence are driving growth in MEA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 RANKING OF PLAYERS, 2018
10.3 COMPETITIVE SCENARIO
10.4 VENDOR DIVE OVERVIEW
10.5 VENDOR INCLUSION CRITERIA
10.6 VENDOR DIVE
10.6.1 VISIONARY LEADERS
10.6.2 INNOVATORS
10.6.3 DYNAMIC DIFFERENTIATORS
10.6.4 EMERGING COMPANIES
11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 GE HEALTHCARE
11.2 SIEMENS HEALTHINEERS (A SUBSIDIARY OF SIEMENS GROUP)
11.3 PHILIPS
11.4 CANON, INC.
11.5 SHIMADZU CORPORATION
11.6 STRYKER CORPORATION
11.7 FLUOPTICS
11.8 UNITED IMAGING HEALTHCARE CO., LTD.
11.9 HITACHI, LTD.
11.10 ESAOTE SPA
11.11 NEUSOFT CORPORATION
11.12 MINDRAY MEDICAL INTERNATIONAL LIMITED (A SUBSIDIARY OF
EXCELSIOR UNION, LTD.)
11.13 MITAKA USA, INC.
11.14 CURADEL, LLC
11.15 IMPEDIMED LIMITED
11.16 OTHER COMPANIES
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING SYSTEMS
TABLE 2 KEY INVESTMENTS BY GOVERNMENT BODIES IN
THE DIAGNOSTIC IMAGING MARKET
TABLE 3 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 4 COMPARISON OF DIAGNOSTIC IMAGING TESTS FOR LYMPHEDEMA
TABLE 5 LYMPHOSCINTIGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 6 LYMPHOSCINTIGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 8 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 9 ULTRASOUND IMAGING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 ULTRASOUND IMAGING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 12 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 13 X-RAY LYMPHOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 14 X-RAY LYMPHOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15 BIOIMPEDANCE ANALYSIS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 16 BIOIMPEDANCE ANALYSIS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 18 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 19 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20 ICG LYMPHOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 21 ICG LYMPHOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 23 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24 LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 25 LYMPHEDEMA DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2017–2024 (USD MILLION)
TABLE 26 LYMPHEDEMA DIAGNOSTICS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 27 LYMPHEDEMA DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2017–2024 (USD MILLION)
TABLE 28 LYMPHEDEMA DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 29 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 30 LYMPHEDEMA DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2017–2024 (USD MILLION)
TABLE 31 LYMPHEDEMA DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 32 LYMPHEDEMA DIAGNOSTICS MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2017–2024 (USD MILLION)
TABLE 33 LYMPHEDEMA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 34 LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 35 LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 38 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 39 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 40 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 41 US: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 42 US: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 43 US: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 44 US: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 45 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 46 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 47 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 48 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 49 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 51 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 52 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 53 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 54 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 55 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 56 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 57 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 58 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 59 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 60 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 61 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 62 UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 63 UK: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 64 UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 65 UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 66 ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 67 ROE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 68 ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 69 ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 70 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 71 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 72 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 73 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 74 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 75 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 76 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 77 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 78 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 79 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 80 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 81 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 82 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 83 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 84 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 86 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 87 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 88 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 89 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 90 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 91 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 92 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 93 ROW: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 94 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 95 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 96 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 97 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 98 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 99 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 100 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 101 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 104 PRODUCT LAUNCHES, ENHANCEMENTS, & APPROVALS
TABLE 105 PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS
TABLE 106 ACQUISITIONS
TABLE 107 EXPANSIONS
TABLE 1 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING SYSTEMS
TABLE 2 KEY INVESTMENTS BY GOVERNMENT BODIES IN
THE DIAGNOSTIC IMAGING MARKET
TABLE 3 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 4 COMPARISON OF DIAGNOSTIC IMAGING TESTS FOR LYMPHEDEMA
TABLE 5 LYMPHOSCINTIGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 6 LYMPHOSCINTIGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 8 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 9 ULTRASOUND IMAGING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 ULTRASOUND IMAGING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 12 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 13 X-RAY LYMPHOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 14 X-RAY LYMPHOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15 BIOIMPEDANCE ANALYSIS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 16 BIOIMPEDANCE ANALYSIS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 18 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 19 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20 ICG LYMPHOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 21 ICG LYMPHOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 23 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24 LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 25 LYMPHEDEMA DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2017–2024 (USD MILLION)
TABLE 26 LYMPHEDEMA DIAGNOSTICS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 27 LYMPHEDEMA DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2017–2024 (USD MILLION)
TABLE 28 LYMPHEDEMA DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 29 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 30 LYMPHEDEMA DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2017–2024 (USD MILLION)
TABLE 31 LYMPHEDEMA DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 32 LYMPHEDEMA DIAGNOSTICS MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2017–2024 (USD MILLION)
TABLE 33 LYMPHEDEMA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 34 LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 35 LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 38 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 39 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 40 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 41 US: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 42 US: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 43 US: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 44 US: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 45 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 46 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 47 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 48 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 49 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 51 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 52 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 53 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 54 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 55 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 56 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 57 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 58 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 59 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 60 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 61 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 62 UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 63 UK: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 64 UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 65 UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 66 ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 67 ROE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 68 ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 69 ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 70 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 71 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 72 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 73 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 74 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 75 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 76 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 77 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 78 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 79 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 80 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 81 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 82 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 83 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 84 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 86 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 87 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 88 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 89 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 90 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 91 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 92 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 93 ROW: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 94 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 95 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 96 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 97 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 98 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 99 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 100 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 101 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 104 PRODUCT LAUNCHES, ENHANCEMENTS, & APPROVALS
TABLE 105 PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS
TABLE 106 ACQUISITIONS
TABLE 107 EXPANSIONS
LIST OF FIGURES
FIGURE 1 LYMPHEDEMA DIAGNOSTICS MARKET: RESEARCH METHODOLOGY STEPS
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARIES: GLOBAL LYMPHEDEMA DIAGNOSTICS MARKET
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 5 MARKET SIZE ESTIMATION: LYMPHEDEMA DIAGNOSTICS MARKET
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
FIGURE 8 GEOGRAPHIC ANALYSIS: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019
FIGURE 9 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2019 VS. 2024
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE LYMPHEDEMA DIAGNOSTICS MARKET
FIGURE 11 RISING PREVALENCE OF LYMPHEDEMA—A MAJOR FACTOR DRIVING THE MARKET FOR LYMPHEDEMA DIAGNOSTICS
FIGURE 12 NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, IN 2019
FIGURE 13 NEAR-INFRARED FLUORESCENCE IMAGING TO REGISTER THE HIGHEST GROWTH IN THE LYMPHEDEMA DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
FIGURE 14 ICG LYMPHOGRAPHY SEGMENT WILL CONTINUE TO DOMINATE THE NEAR-INFRARED FLUORESCENCE IMAGING MARKET IN 2024
FIGURE 15 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 16 LYMPHEDEMA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 18 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 19 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 20 GE HEALTHCARE HELD THE LEADING POSITION IN THE LYMPHEDEMA DIAGNOSTICS MARKET IN 2018
FIGURE 21 LYMPHEDEMA DIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2018
FIGURE 22 GE HEALTHCARE: COMPANY SNAPSHOT
FIGURE 23 SIEMENS AG: COMPANY SNAPSHOT
FIGURE 24 PHILIPS: COMPANY SNAPSHOT
FIGURE 25 CANON, INC.: COMPANY SNAPSHOT
FIGURE 26 SHIMADZU CORPORATION: COMPANY SNAPSHOT
FIGURE 27 STRYKER CORPORATION: COMPANY SNAPSHOT
FIGURE 28 HITACHI, LTD.: COMPANY SNAPSHOT
FIGURE 29 NEUSOFT CORPORATION: COMPANY SNAPSHOT
FIGURE 30 IMPEDIMED LIMITED: COMPANY SNAPSHOT
FIGURE 1 LYMPHEDEMA DIAGNOSTICS MARKET: RESEARCH METHODOLOGY STEPS
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARIES: GLOBAL LYMPHEDEMA DIAGNOSTICS MARKET
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 5 MARKET SIZE ESTIMATION: LYMPHEDEMA DIAGNOSTICS MARKET
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
FIGURE 8 GEOGRAPHIC ANALYSIS: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019
FIGURE 9 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2019 VS. 2024
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE LYMPHEDEMA DIAGNOSTICS MARKET
FIGURE 11 RISING PREVALENCE OF LYMPHEDEMA—A MAJOR FACTOR DRIVING THE MARKET FOR LYMPHEDEMA DIAGNOSTICS
FIGURE 12 NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, IN 2019
FIGURE 13 NEAR-INFRARED FLUORESCENCE IMAGING TO REGISTER THE HIGHEST GROWTH IN THE LYMPHEDEMA DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
FIGURE 14 ICG LYMPHOGRAPHY SEGMENT WILL CONTINUE TO DOMINATE THE NEAR-INFRARED FLUORESCENCE IMAGING MARKET IN 2024
FIGURE 15 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 16 LYMPHEDEMA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 18 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 19 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 20 GE HEALTHCARE HELD THE LEADING POSITION IN THE LYMPHEDEMA DIAGNOSTICS MARKET IN 2018
FIGURE 21 LYMPHEDEMA DIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2018
FIGURE 22 GE HEALTHCARE: COMPANY SNAPSHOT
FIGURE 23 SIEMENS AG: COMPANY SNAPSHOT
FIGURE 24 PHILIPS: COMPANY SNAPSHOT
FIGURE 25 CANON, INC.: COMPANY SNAPSHOT
FIGURE 26 SHIMADZU CORPORATION: COMPANY SNAPSHOT
FIGURE 27 STRYKER CORPORATION: COMPANY SNAPSHOT
FIGURE 28 HITACHI, LTD.: COMPANY SNAPSHOT
FIGURE 29 NEUSOFT CORPORATION: COMPANY SNAPSHOT
FIGURE 30 IMPEDIMED LIMITED: COMPANY SNAPSHOT
